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he ability of stem cells to generate distinct fates is
critical for the generation of cellular diversity during
development. Central nervous system (CNS) stem
cells respond to bone morphogenetic protein (BMP) 4 by
differentiating into a wide variety of dorsal CNS and neural
 
crest cell types. We show that distinct mechanisms are
responsible for the generation of two of these cell types,
smooth muscle and glia. Smooth muscle differentiation
requires BMP-mediated Smad1/5/8 activation and predomi-
nates where local cell density is low. In contrast, glial differen-
tiation predominates at high local densities in response to
T
 
BMP4 and is speciﬁcally blocked by a dominant-negative
mutant Stat3. Upon BMP4 treatment, the serine-threo-
nine kinase FKBP12/rapamycin-associated protein (FRAP),
mammalian target of rapamycin (mTOR), associates with
Stat3 and facilitates STAT activation. Inhibition of FRAP
prevents STAT activation and glial differentiation. Thus,
glial differentiation by BMP4 occurs by a novel pathway
mediated by FRAP and STAT proteins. These results suggest
that a single ligand can regulate cell fate by activating distinct
cytoplasmic signals.
 
Introduction
 
Recent work suggests that the wide arrays of cell types that
can be generated during development depend critically on
the actions of extracellular signals on multipotent precur-
sors (Dorsky et al., 2000; Panchision and McKay, 2002;
Zhu and Emerson, 2002). Isolated central nervous system
(CNS)* stem cells can be exposed to novel environments to
differentiate into both CNS fates as well as non-CNS fates
including skeletal muscle and hematopoetic derivatives
(Valtz et al., 1991; Bjornson et al., 1999; Galli et al., 2000).
Similarly, cell populations enriched for hematopoietic stem
cells can differentiate into hepatocytes, cardiomyocytes, and
skeletal muscle cells (Gussoni et al., 1999; Jackson et al.,
1999; Lagasse et al., 2000). These results have provoked a
great deal of interest in the fundamental mechanisms con-
trolling cell fate choice and in the potential for exploiting
this knowledge for new therapies.
Cultured stem cells are increasingly used to analyze mech-
anisms of cellular differentiation because of the easy access to
large numbers of self-renewing cells that exhibit rapid, con-
trolled and reproducible differentiation. We have previously
shown that CNS stem cells isolated from the embryonic rodent
brain can be expanded in large numbers using the mitogen
basic FGF (bFGF) to maintain self-renewal (Vicario-Abejon
et al., 1995; Johe et al., 1996). Upon bFGF withdrawal,
these cells will differentiate into the three characteristic CNS
lineages: neurons, astrocytes, and oligodendrocytes (Johe et
al., 1996). Furthermore, they can be efficiently redirected to
specific CNS fates by the addition of single extracellular factors
such as platelet-derived growth factor, triiodothyronine, and
ciliary neurotrophic factor (CNTF) (Johe et al., 1996).
CNTF rapidly and robustly instructs CNS stem cells to a
glial fate and requires the actions of S
 
tat
 
3 (Bonni et al.,
1997; Rajan and McKay, 1998).
Bone morphogenetic proteins (BMPs) have diverse actions
on the fate choice and differentiation of CNS stem cells during
development. BMPs induce dorsal precursor fates, including
roof plate, choroid plexus epithelium, and neural crest (Shah
et al., 1996; Liem et al., 1997; Sela-Donenfeld and Kalcheim,
1999; Panchision et al., 2001), and induce apoptosis or termi-
nal differentiation in the developing neural tube (Graham et
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al., 1996; Furuta et al., 1997; Li et al., 1998; Panchision et
al., 2001). BMP stimulation of CNS precursors in vitro
leads to differentiation into CNS neurons (Mabie et al.,
1999) and glia (Gross et al., 1996) and neural crest deriva-
tives such smooth muscle, peripheral neurons, and Schwann
cells (Mujtaba et al., 1998; Molne et al., 2000; Panchision et
al., 2001). These diverse responses to BMPs may be due to
(a) other signals that modulate the response to BMPs (Sun et
al., 2001; White et al., 2001) and/or (b) the activation of
different BMP signal transduction pathways. Here we show
that the differentiation of two distinct cell fates, smooth
muscle and glia, is modulated by density and is controlled by
alternative use of two distinct cytoplasmic BMP pathways.
 
Results
 
Local density affects stem cell fate choice in response 
to BMPs
 
BMPs are known to instruct CNS stem cells to dorsal fates,
such as neural crest, and to subsequently differentiate these
dorsalized precursors to peripheral neurons, Schwann cells,
and smooth muscle (Mujtaba et al., 1998; Molne et al.,
2000; Panchision et al., 2001). In response to BMP2 or
BMP4 treatment, CNS stem cells at low local density gave
rise to a high proportion of smooth muscle cells, as mea-
sured by smooth muscle 
 
 
 
-actin (SMA) staining. The gener-
ation of smooth muscle was more efficient with increasing
concentrations of BMP4 (Table I). At higher local densities,
stem cells gave rise to high proportions of glia, as measured
by glial fibrillary acidic protein (GFAP) (Fig. 1).
To determine whether these two fates can arise from the
same cell, we plated cortical stem cells at clonal density (35
cells/cm
 
2
 
) in the presence of bFGF as a mitogen. The cells
were treated with BMP4 for 2 d, starting either immediately
upon plating (Fig. 1 A) or after 6 d of bFGF expansion (Fig.
1 C), and allowed to terminally differentiate in the presence
of BMP4 alone. Cultures that received BMP treatment im-
mediately upon plating efficiently and uniformly generated
small, sparse clones of 
 
 
 
2–30 cells that were almost exclu-
sively SMA
 
 
 
 (Fig. 1 B; Table I). In cultures that received 6 d
of expansion in bFGF alone, clones had 
 
 
 
180–330 cells
with an average cell cycle time of 
 
 
 
18 h. At the initiation of
BMP treatment, the center of each clone had reached a high
local density while the periphery of the clone remained
sparse. By the end of BMP treatment, the center of each
clone was almost exclusively GFAP
 
 
 
 glia while the periphery
of each clone was almost exclusively SMA
 
 
 
 smooth muscle
(Fig. 1 D). The boundary between the dense core and the
sparse periphery of clones consisted of a mixture of glia and
smooth muscle, as well as GFAP
 
 
 
SMA
 
 
 
 or GFAP
 
low
 
SMA
 
low
 
cells that had morphologies intermediate between the sheet-
like morphology of smooth muscle and the process-bearing
morphology of the glia.
Neurons were also generated in both low- and high-density
cultures, but in the absence of additional survival factors, the
BMP-generated neurons usually died during differentiation.
Thus, all clones in these BMP-treated cultures consisted pre-
dominantly of smooth muscle and glia. In contrast, stem cell
clones grown to either low or high local density in the absence
of BMP treatment generated only CNS neurons, astrocytes,
 
Table I. 
 
Efficiency of smooth muscle differentiation in
low-density culture
BMP4 Clone size Percent SMA
 
 
 
 cells
 
ng/ml
 
0 mass culture 0
1 mass culture 22.2 
 
 
 
 14.0
5 mass culture 55.3 
 
 
 
 14.3
10 mass culture 61.0 
 
 
 
 21.7
20 mass culture 81.5 
 
 
 
 6.2
10 1–5 cells 74.2 
 
 
 
 6.8
10 6–10 cells 85.9 
 
 
 
 6.9
For mass culture, cells were plated at 3,500 cells/cm
 
2
 
 and immediately
treated with BMP4 for 2 d with mitogen and 4 d after mitogen withdrawal.
For clonal analysis, cells were plated at 35 cells/cm
 
2
 
 and immediately
treated with 10 ng/ml BMP4 for 2 d with mitogen and 4 days after mitogen
withdrawal. No GFAP
 
 
 
 cells were seen in these clones. Mean 
 
 
 
 SEM; 
 
n
 
 =
4 for mass culture, 
 
n
 
 = 32 for 1–5 cell clones, and 
 
n
 
 = 9 for 6–10 cell clones.
Figure 1. BMP4-treated cortical stem cells will 
differentiate into smooth muscle or glia depending 
on local density. (A) Low-density treatment schedule. 
E14.5 cortical stem cells were plated at clonal density 
(35 cell/cm
2) and instructed immediately with BMP4 
along with bFGF (10 ng/ml each) for 2 d, followed 
by differentiation with BMP4 alone for 4 d. (B) This 
results in small clones with a low local cell density 
and differentiation into almost exclusively SMA
  
smooth muscle. (C) High-density treatment schedule. 
E14.5 cortical stem cells were plated at clonal 
density, expanded in bFGF to increase local cell 
density, and then instructed with BMP4 along with 
bFGF for 2 d, followed by differentiation with 
BMP4 alone for 4 d. (D) This results in clones with 
a high central density (GFAP
  glia) and a low density 
around the periphery (SMA
  smooth muscle). 
These regions meet at a boundary of interspersed 
smooth muscle, glia, and cells with a transitional 
morphology that have weak or absent staining for 
these markers. Rectangles in cartoon clones indicate 
area shown in fluorescent images. Bars, 100  m.T
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and oligodendrocytes, as reported in previous studies (Johe et
al., 1996). This indicates that the BMP-induced generation of
neural crest derivatives, such as smooth muscle (Table I), is an
efficient response of cortical stem cells and not of any con-
taminating cell type. On the basis of these observations, we
sought to determine how this difference in cell density affects
the fate choice of stem cells in response to BMPs.
 
BMP regulates smooth muscle and glial fates by signaling 
through the SMAD and STAT pathways, respectively
 
BMPs generate many responses by activating the SMAD
family of DNA binding proteins (Miyazono, 1999). Tran-
sient transfection assays were used to determine if SMAD
activation was necessary for generation of either or both of
the fates. Cells were transfected with a construct that consti-
tutively expresses high levels of HA-tagged Smad7, an en-
dogenous inhibitory SMAD that functions as a dominant
negative (Souchelnytskyi et al., 1998; Ishisaki et al., 1999).
The transfected protein was allowed to express for 3 d, after
which BMP treatment was initiated. Of all HA–Smad7-
transfected cells, 77% differentiated into glia whereas 
 
 
 
16%
differentiated into smooth muscle (Table II).
Previous work has shown that STAT activation is required
for CNTF-induced astrocytic differentiation of CNS stem
cells (Bonni et al., 1997; Rajan and McKay, 1998). We
sought to determine if BMP-mediated glial differentiation
was also dependent on STAT activation by transfecting stem
cells with a FLAG-tagged dominant-negative Stat3 followed
by BMP treatment. Of all cells transfected with dominant-
negative Stat3 (Horvath et al., 1995), 
 
 
 
13% differentiated
into glia whereas 85% differentiated into smooth muscle in
response to BMP4 (Table II). This result suggests that
SMAD signaling is required for smooth muscle but not glial
differentiation, whereas STAT signaling is required for glial
but not smooth muscle differentiation.
These data suggest that smooth muscle and glial fates
are independently controlled by SMAD and STAT activa-
tion, respectively. We verified the biochemical activation of
SMAD proteins by performing immunoblotting assays
with an antibody recognizing the phosphorylated forms of
Smad1, 5, and 8 (Faure et al., 2000) on whole cell extracts
prepared after a 1-h factor treatment. Although bFGF and
CNTF each have strong proliferative and differentiative ef-
fects on stem cells (Johe et al., 1996; Rajan and McKay,
1998), they had no effect on the activation of Smad1/5/8
(Fig. 2 A). In contrast, BMP4 robustly activated Smad1/5/8
in both low- and high-density cultures (Fig. 2 A, lanes 3 and
 
6). This activation occurred within 30 min and continued
beyond 4 h of BMP4 treatment (Fig. 2 B).
We verified STAT activation by electrophoretic mobility
shift assay (EMSA), which measures the extent of binding of
phosphorylated STAT proteins to a DNA oligonucleotide
containing a specific recognition site. As we have previously
shown (Rajan and McKay, 1998), the principal band con-
sisted of a Stat3 homodimer complex with the oligonucle-
otide (Fig. 3 A, arrow), whereas the fainter band below it
consisted of Stat3/Stat1 heterodimer complexes with the
oligonucleotide. We found that basal levels of Stat3 activa-
tion were greater in high-density versus low-density cultures
(Fig. 3, lanes 1 and 4). As expected, CNTF treatment dra-
matically increased Stat3 activation in both low- and high-
density cultures (Fig. 3, lanes 2 and 5). BMP4 treatment
had no effect on Stat3 activation in low-density cultures but
activated Stat3 in high-density cultures (Fig. 3, lanes 3 and
6). These results indicate that although BMP4 activates
SMADs in both low- and high-density cultures, it activates
STATs only in high-density cultures that have higher basal
levels of STAT activation and that give rise to glia. They
also suggest the presence of a density-mediated signal that
causes STAT activation.
 
Table II. 
 
Effect of STAT or SMAD inhibition on
BMP4-induced differentiation
Transfection Markers expressed Percent cells coexpressing
 
dnS
 
tat
 
3–FLAG FLAG
 
 
 
/GFAP
 
 
 
12.7 
 
 
 
 4.9
FLAG
 
 
 
/SMA
 
 
 
85.2 
 
 
 
 8.9
Smad7–HA HA
 
 
 
/GFAP
 
 
 
77.1 
 
 
 
 12.5
HA
 
 
 
/SMA
 
 
 
15.6 
 
 
 
 5.8
Cells were plated at 3,500 cells/cm
 
2
 
, cultured with mitogen for 1 d before
transfection and 3 d after transfection, and then treated with 10 ng/ml BMP4
for 3 d with mitogen and 3 d after mitogen withdrawal (see Materials and
methods). Mean 
 
 
 
 SEM, 
 
n
 
 = 4.
Figure 2. BMP4 causes SMAD activation in both low- and high-
density stem cell cultures. Cells were treated with bFGF   CNTF or 
BMP4 (10 ng/ml each) for 1 h. Normalized whole cell extracts were 
used for Western blot analysis with an anti-phosphoSMAD antibody 
recognizing activated Smad1, 5, and 8 (47 kD for Smad1 and 5; 40 kD 
for Smad8). (A) BMP4 treatment causes SMAD activation in both 
low- (lane 3) and high-density (lane 6) cultures. Control (lanes 1 and 4) 
or CNTF-treated (lanes 2 and 5) stem cells have no SMAD activation. 
(B) Time course of SMAD phosphorylation during BMP4 (10 ng/
ml)   bFGF (10 ng/ml) treatment of high-density cultures. BMP4 
causes SMAD activation within 30 min (lane 2) that decreases at 8 h 
(lane 6). The lower panels of both figures show a Ponceau S staining 
of the nitrocellulose filter to demonstrate normalized loading of
proteins across all lanes.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
914 The Journal of Cell Biology 
 
|
 
 
 
Volume 161, Number 5, 2003
 
We performed immunoblots with an antibody specific to
Stat3 phosphorylated on serine 727 (ser727) to verify BMP-
mediated phosphorylation at this site (Fig. 3 B), which is
one of the activation events that Stat3 undergoes (Zhang et
al., 1995). Phosphorylation of ser727 was increased at 20
min after exposure to BMP4 and this elevation was long last-
ing. We also performed immunocytochemistry for phospho-
ser727 Stat3 on mouse stem cell cultures that were treated
with BMP4 (Fig. 3, C and D). Mouse cortical stem cells
were seeded at 2,500 cells/cm
 
2
 
, expanded for 5 d, and
treated with 10 ng/ml BMP4 before fixation. Elevated levels
of phospho-ser727 Stat3–specific staining were seen in cul-
tures treated with BMP4, indicated by the increased red
staining in Fig. 3 D. These data indicate that BMP4 causes
activation of STAT proteins in stem cells and specifically
phosphorylates Stat3 at ser727.
Maximal activation of STAT proteins by BMP was seen at
8 h. This treatment is prolonged when compared with
CNTF, which causes maximal STAT activation at 15 min to
1 h. The long time required for BMP4 to activate STAT
proteins suggests that some intermediary signal, perhaps a
CNTF-like activity, becomes transcriptionally activated and
that this is responsible for the activation of Stat3. We tested
this possibility by treating the stem cells with the transcrip-
tional inhibitor 
 
 
 
-amanitin, which acts as a competitive in-
hibitor of RNA polymerase II (Wieland and Faulstich,
1978). Cotreatment of stem cells with 
 
 
 
-amanitin did not
block BMP4-mediated Stat3 binding (Fig. 4, compare lanes
4 and 5 with 9 and 10). These results make it unlikely that
Stat3 activation requires a transcriptionally induced inter-
mediate and instead suggests that BMP4 activates Stat3 di-
rectly through cytoplasmic signaling.
 
BMP4 induces glial fate through FRAP–Stat3
 
As there are no known mechanisms linking BMPs to STAT
activation, we sought to determine the pathway by which
this occurs. Previous studies showed that TGF
 
 
 
 receptors
bind to the immunophilin FKBP12, which prevents SMAD
activation in the absence of ligand binding (Chen et al.,
1997; Stockwell and Schreiber, 1998). We performed
coimmunoprecipitation experiments to see if FKBP12
binds BMP receptors in our stem cells. Nondenaturing
cell extracts were immunoprecipitated with an antibody to
FKBP12, and the complexes were analyzed on immunoblots
Figure 3. BMP4 causes STAT activation 
only in high-density stem cell cultures. 
(A) Cells were treated with bFGF   CNTF 
for 1 h or BMP4 for 8 h (10 ng/ml each). 
Nuclear extracts were subjected to 
EMSA analysis using a 
32P-radiolabeled 
STAT binding site (double-stranded oligo-
nucleotide) to measure STAT activation. 
Basal (bFGF treated only) levels of STAT 
binding are minimal in low-density cultures 
(lane 1) but are increased in high-density 
cultures (lane 4). CNTF treatment causes a 
strong increase in STAT binding in both 
low- (lane 2) and high-density (lane 5) 
cultures. BMP4 treatment of low-density 
cultures (lane 3) has no effect on STAT 
binding, whereas BMP4 treatment of high-
density cultures (lane 6) causes increased 
STAT binding. The arrow marks complexes 
of Stat3 homodimers with STAT binding 
site oligonucleotides. The fainter bands below are complexes of Stat1 and Stat3 heterodimers with STAT binding site oligonucleotides. 
(B, top) Cortical stem cells were treated with BMP4 for 20, 40, or 60 min at 10 ng/ml, denaturing extracts prepared and analyzed on SDS-PAGE 
gels. The immunoblot was probed sequentially with antibodies specific for Stat3 phosphorylated on Ser727 and panStat3 for total levels of 
Stat3. BMP causes phosphorylation of Stat3 on Ser727, as seen in the top band of the figure. (B, bottom) Mouse cortical stem cells were cultured 
as described in the Materials and methods section and treated with BMP4 for 20 min before fixation. Cells were then stained with an antibody 
specific to the phosphor-ser727 Stat3 protein and viewed by indirect immunofluorescence. The DAPI staining is blue, and pser727Stat3 staining 
is red.
Figure 4. BMP4-mediated activation of Stat3 
does not require transcription. Cortical stem cells 
were expanded in mass culture to high local density 
using bFGF (10 ng/ml) and then treated with 
10 ng/ml BMP4 for the time points indicated in the 
absence (lanes 1–5) or presence (lanes 6–10) of 
5  g/ml  -amanitin. Control samples were treated 
with  -amanitin alone (lanes 11–14). Nuclear 
extracts were subjected to EMSA analysis using a 
32P-radiolabeled STAT binding site (double-stranded 
oligonucleotide) to measure STAT activation. 
Inhibition of transcription with  -amanitin does 
not prevent Stat3 binding in response to BMP4.T
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with an antibody to BMP receptor type one A (BMPR-IA).
We found that FKBP12 complexed with BMPR-IA in CNS
stem cells, and that this complex dissociated when cells were
treated with BMP4 (Fig. 5 A). The complex almost com-
pletely dissociated by 8 h after BMP4 treatment, when com-
pared with the control, i.e., bFGF alone.
FKBP12 is a 12-kD protein that complexes with the im-
munosuppressant macromolecules rapamycin and FK506.
Specifically, FKBP12 complexes with rapamycin to block
the actions of the serine-threoine kinase FKBP12/rapamy-
cin-associated protein (FRAP), mammalian target of rapa-
mycin (mTOR) (Choi et al., 1996; Kuruvilla and Schreiber,
1999). EMSA assays were performed on stem cells treated
for 9 h with BMP4 in the presence or absence of a pretreat-
ment of rapamycin. We found that rapamycin blocked the
BMP4-mediated activation of Stat3 in high-density cultures
as measured by EMSA (Fig. 5 B). These observations impli-
cate FRAP as the mediator of STAT activation in high-den-
sity cultures.
The observations that BMP-mediated activation is blocked
by rapamycin and the correlated release of FKBP12 from
 
the BMP receptor implicate FRAP as the mediator of STAT
activation. A previous study has shown that FRAP can phos-
phorylate STAT proteins in response to CNTF (Yokogami
et al., 2000). As this would involve direct interaction be-
tween FRAP and Stat3, we determined if BMP signaling in-
creases complex formation between the two proteins. FRAP
was immunoprecipitated from nondenaturing cell extracts,
and the immunoprecipitated proteins were subsequently
immunoblotted with an anti-Stat3 antibody. BMP treat-
ment of CNS stem cells led to increased interaction
of FRAP and Stat3 proteins by coimmunoprecipitation,
greater than that seen with CNTF (Fig. 5 C). The binding
of FRAP to Stat3 in response to BMP stimulation (Fig. 5 C)
and the inhibition of Stat3 activation by rapamycin (Fig. 5
B) suggest that BMP4 activates Stat3 via a FRAP-mediated
pathway.
As more direct evidence that FRAP is instrumental in me-
diating STAT activation, and hence glial differentiation,
downstream of BMP, we determined the effect of two dom-
inant-negative forms of FRAP on BMP-mediated astrocytic
differentiation. The Trp2027Phe point mutation renders
Figure 5. BMP4-mediated activation of 
Stat3, and glial differentiation, requires 
FRAP. (A) BMP4 causes dissociation of 
BMPR-IA and FKBP12. Cells were treated 
with BMP4 (10 ng/ml) for the duration 
of 30 min to 8 h, control sample was 
treated with bFGF for 8 h. Normalized, 
nondenatured whole cell lysates were 
immunoprecipitated with anti-FKBP12 
before Western blot analysis using anti–
BMPR-IA. BMP4 treatment causes a 
dissociation of BMPR-IA–FKBP12 
complexes (arrow indicates 64-kD band). 
The lower panel shows the levels of 
FKBP12 in the immunoprecipitated 
complexes across all lanes. (B) BMP-
mediated STAT activation is blocked by 
rapamycin. High-density stem cell cultures 
with enhanced STAT binding (lane 1) 
showed a further increase in STAT binding 
after BMP4 (10 ng/ml) treatment for 9 h 
(lane 2). Pretreatment with rapamycin 
for 12 h before BMP4 addition blocked 
further Stat3 binding (lane 3). (C) BMP4 
treatment causes increased complex 
formation between FRAP and Stat3. Cells 
were treated with bFGF alone or with 
CNTF for 15 min or BMP4 for 4 h 
(10 ng/ml each). Note that 15 min 
represents the time of maximal Stat3 
activation by CNTF. Normalized, 
nondenatured whole cell lysates were 
immunoprecipitated with anti-FRAP 
before Western blot analysis using anti-
Stat3. Arrow indicates 91-kD band. Estimation of the levels of FRAP in the immunoprecipitated complexes could not be performed under the 
conditions optimal for Stat3 detection because FRAP is a substantially larger protein, 287 kD. (D) Activated FRAP is required for BMP-mediated 
glial differentiation. Cortical stem cells were transfected with NH2-terminal FLAG-tagged dominant-negative FRAP mutants, Asp2357Glu, 
which is kinase dead, and Trp2027Phe, which is FRB defective. Cells were transfected for 3 h, treated with BMP4 in the presence of bFGF (both 
10 ng/ml) for 2 d and BMP4 alone for 4 d, and then fixed and stained for GFAP and FLAG. Cells were counted by indirect immunofluorescence, 
and those expressing GFAP were calculated as a percentage of cells expressing FLAG protein. Control cultures were transfected with a GFP-
expressing plasmid, which had no effect on BMP-mediated glial differentiation. (E) 80% of GFP-positive cells coexpress GFAP, whereas 25% 
of mutant FRAP–expressing cells coexpress GFAP, indicating that dominant-negative FRAP inhibits BMP-mediated GFAP expression. Mean 
GFAP
  cells as a percentage of total transfected cells, **P   0.001. Bar, 20  m.T
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FRAP defective in the FKBP12-rapamycin binding (FRB)
domain, whereas Asp2357Glu point mutation deletes the
kinase function of FRAP (Vilella-Bach et al., 1999). Both
the constructs we have used are NH
 
2
 
-terminal FLAG
tagged. About 25% of stem cells transfected with the domi-
nant-negative forms of FRAP differentiate into glia upon
BMP treatment (Fig. 5, D and E), whereas in a control
transfection with a GFP construct under identical experi-
mental conditions, 80% of the culture differentiated into
glia. These data indicate that FRAP activation is required for
BMP-mediated glial differentiation.
 
BMP4-induced glial differentiation is rapamycin 
sensitive, whereas smooth muscle differentiation is 
rapamycin insensitive
 
We additionally looked at rapamycin inhibition of FRAP on
fate choice. Stem cells that received no treatment before mi-
togen withdrawal generated glia with weak to moderate
GFAP staining and an immature morphology (Fig. 6 A).
Stem cells that received CNTF before mitogen withdrawal
generated intensely stained GFAP
 
 
 
 cells with a mature, stel-
late astrocytic morphology (Fig. 6 B), as described previously
(Johe et al., 1996; Rajan and McKay, 1998). Treatment with
BMP4 before mitogen withdrawal generated glia with strong
GFAP staining and distinctly flattened morphology (Fig. 6
C). Stem cells that received BMP4 and rapamycin showed a
dramatically reduced number of GFAP
 
 
 
 cells, even in areas
with high local density (Fig. 6 D). Additionally, we treated
stem cells with FK506, another drug that complexes with
FKBP12 but inhibits the phosphatase calcineurin (Abraham
and Wiederrecht, 1996). We found that FK506 had no effect
on the generation of glia by BMP4 (Fig. 6 E).
We counted cells in the transitional zones that give rise to
both glia and smooth muscle in medium- and high-density
Figure 6. BMP4-mediated glial differentiation is rapamycin sensitive, whereas smooth muscle differentiation is rapamycin insensitive. 
CNS stem cells were grown to medium or high local density before treatment. (A–E) Dense core of E14.5 cortical stem cell colonies after 
treatment and immunostaining for GFAP. (A) Simple withdrawal of bFGF (control) yields glia with immature morphology. (B) Treatment with 
CNTF before mitogen withdrawal yields CNS astrocytes with mature morphology. (C) Treatment with BMP4 before mitogen withdrawal 
yields glia with more flattened morphology. (D) Cotreatment with rapamycin blocks BMP4-mediated glial differentiation. (E) Cotreatment 
with FK506 has no effect on BMP4-mediated glial differentiation. (F and G) Quantitation of GFAP and SMA staining at the transitional zones 
in (F) medium-size/density E14.5 colonies, (G) large, high-density E14.5 colonies, and (H) medium-size/density adult colonies. Rectangles in 
cartoon colonies mark transitional zones chosen for quantitation; note that these zones have sizeable numbers of GFAP
 SMA
  cells. Mean 
GFAP
  or SMA
  cells as percentage of total cells   SEM (n   6–9). Bar, 100  m.T
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clones (Fig. 6, F and G). Rapamycin treatment caused a
fourfold reduction in the generation of glia but had no sig-
nificant effect on the number of smooth muscle cells. How-
ever, the number of GFAP
 
 
 
SMA
 
 
 
 or GFAP
 
low
 
SMA
 
low
 
 cells
with a transitional morphology was increased, and there re-
mained large numbers of SMA
 
 
 
 cells in the periphery. In all
conditions, there was no observable cell death up to the
time of fixation (4 d after withdrawal), indicating that the
effect of treatment on gliogenesis was not the result of nega-
tive selection.
We then looked at the effect of rapamycin in adult stem
cells. These cells are multipotent based on clonal assays
(Johe et al., 1996), but BMP treatment promotes efficient
glial differentiation even at lower densities that would pro-
mote smooth muscle differentiation in fetal stem cells. In
these cells, rapamycin treatment caused a twofold reduc-
tion in the generation of glia and caused a twofold increase
in the number of smooth muscle cells (Fig. 6 H). Thus, in-
hibition of FRAP specifically blocks the glial fate in both
fetal and adult stem cells and redirects adult stem cells to a
smooth muscle fate. These results are all consistent with
the conclusion that BMP4 causes glial differentiation by
FRAP-mediated Stat3 activation and smooth muscle dif-
ferentiation by a FRAP-independent, SMAD-mediated
mechanism.
 
BMP4 and CNTF have additive effects on 
glial differentiation
 
CNTF and BMPs both cause STAT activation and glial dif-
ferentiation but do so by using different kinases. CNTF pre-
dominantly activates the janus kinases (Kisseleva et al.,
2002), whereas we show that BMPs require a density-depen-
dent signal in addition to FRAP (Fig. 5). Because distinct
pathways are used to activate STAT proteins and cause glial
differentiation, the simultaneous treatment of stem cells
with both ligands might accelerate glial differentiation. Stem
cells were plated at a medium density and treated with either
ligand alone or together. As measured by GFAP expression,
25% of stem cells were differentiated by 24 h after CNTF
treatment, whereas 50% of stem cells differentiated after
48 h. Cotreatment with BMP4 and CNTF increased glia
number from 25 to 60% at 24 h and from 50 to 85% at
48 h (Fig. 7 A).
We then measured the effect of rapamycin during BMP4/
CNTF cotreatment, hypothesizing that this would selec-
tively inhibit BMP-mediated glial differentiation. As ex-
pected, rapamycin treatment abolished the additive effects
that BMP4 lends to CNTF-mediated differentiation. A dose
response of rapamycin shows that the effect is maximal at 1
 
 
 
M (Fig. 7 B); no toxicity was observed at this dose, al-
though higher doses led to cell death. In contrast, FK506
treatment had no effect on the accelerated differentiation by
BMP4 and CNTF (Fig. 7 C). As BMP4 alone eventually in-
duced most high-density stem cells to differentiate to the
glial fate, combined treatment with BMP4 and CNTF ap-
peared to affect the rate of glial differentiation rather than
the final number of glia. Thus, distinct BMP and CNTF cy-
toplasmic signaling pathways converge through STAT pro-
teins to promote glial differentiation.
 
Discussion
 
Combinatorial signals and fate choice
 
Stem cells can generate a number of distinct fates in re-
sponse to BMPs, depending on the context in which BMP
signaling is received. In this study, we use a defined and ho-
mogeneous neural stem cell culture to show that BMP4 effi-
ciently induces the generation of smooth muscle and glia in
a density-dependent manner. We further show that BMP4
activates two distinct cytoplasmic signaling pathways in
stem cells, one mediated by SMAD proteins and the other
by STAT proteins. In low-density cultures with low basal
levels of activated STAT proteins, BMP4 induces smooth
muscle differentiation by activating Smad1/5/8. In high-
density cultures that show higher basal levels of activated
STAT proteins, BMP4 further activates STAT proteins to
generate glia at the expense of smooth muscle. The activa-
tion of STAT proteins by BMP4 involves a novel pathway
Figure 7. BMP4 augments CNTF-mediated glial differentiation 
of CNS stem cells. (A) Cells were treated with bFGF   CNTF 
(10 ng/ml) for 24 or 48 h and stained with anti-GFAP to measure 
glial differentiation. Where indicated, cells were treated with BMP4 
for 4 h before CNTF treatment. BMP4 augments the effect of CNTF 
in generating glia at both 24 and 48 h of treatment. (B) Rapamycin 
blocks this augmentation in a dose-dependent manner (doses in  M). 
(C) Using FK506 (10 nM) instead of rapamycin does not affect the 
BMP-mediated augmentation of glial differentiation. Mean GFAP
  
cells as percentage of total cells   SEM, n   4.T
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mediated by the serine-threonine kinase FRAP. This pro-
vides strong evidence that FRAP and STAT proteins are part
of a newly described signal transduction pathway available in
response to BMPs.
Our results show that fate choice decisions leading to glial
or nonglial fates downstream of BMPs can be made in the
cytoplasm. This provides a novel complement to previous
studies showing that glial differentiation in response to
BMPs is regulated in the nucleus. In these studies, glial dif-
ferentiation requires the coactivators cyclic AMP response
element–binding protein (CBP)/p300 in a complex with
STAT and SMAD proteins (Nakashima et al., 1999). The
differentiation of glia by either BMPs or CNTF is inhibited
by the basic helix-loop-helix protein neurogenin1, which
acts in part by sequestering the CBP–Smad1 complex from
association with STAT proteins. In CNS stem cells express-
ing high levels of neurogenin1, BMPs induce neuronal,
rather than glial, differentiation (Sun et al., 2001). Our re-
sults show that glial versus nonglial fates can also be regu-
lated by alternative cytoplasmic signals. These alternative
pathways are subject to control by density-dependent sig-
nals, consistent with our previous findings (Tsai and Mc-
Kay, 2000). Whereas BMP4 activates SMADs at both low
and high densities, its activation of Stat3 at high density re-
sults in glial differentiation regardless of SMAD activation
(Table II; Figs. 2 and 3). Furthermore, glial differentiation
can occur even when SMAD signaling is inhibited (Table
II). One interpretation of this result is that sufficiently high
levels of STAT activation promote glial differentiation with-
out the requirement for SMADs. Alternatively, SMAD acti-
vation may modify the type of glia that is generated, as evi-
denced by the morphological difference in glia generated
from CNTF- versus BMP-treated stem cells (Figs. 6 and 7).
In addition to density-dependent biases, stem cells also ex-
hibit age-dependent biases in fate choice that mirror the in
vivo developmental progression of cell type differentiation.
Activating BMP signals in vivo results in apoptosis in early
gestation precursors and neurogenesis in midgestation pre-
cursors (Panchision et al., 2001). Similarly, neural stem cells
isolated from progressively older embryos respond to BMPs
first with apoptosis, and then with neuronal and finally glial
differentiation (Gross et al., 1996; Mabie et al., 1999). Our
FRAP inhibition experiments suggest that the same mecha-
nisms for glial differentiation are accessible in both fetal and
adult stem cells and that age-intrinsic differences between
stem cells can be reversible (Fig. 6).
Previous studies have shown that the same signaling mole-
cules can promote either stem cell self-renewal or gliogene-
sis. Notch activation is required for the maintenance of early
gestation neural stem cells (Hitoshi et al., 2002a) but also
promotes gliogenesis in stem cells from older embryos (Tan-
igaki et al., 2001; White et al., 2001). Stat3, which we show
to be activated by BMPs through FRAP, has been shown to
promote both glial differentiation in neural stem cells
(Bonni et al., 1997; Rajan and McKay, 1998) and self-
renewal of embryonic stem cells (Niwa et al., 1998; Nishi-
nakamura et al., 1999; Boeuf et al., 2001) in response to
CNTF or Leukemia inhibitory factor. FRAP signaling is re-
quired for proliferation in mouse embryos and the loss-of-
function phenotype is mimicked by the treatment of em-
bryos with rapamycin (Hentges et al., 2001). Our results
show a novel pathway in which FRAP is recruited to pro-
mote gliogenesis by activating Stat3. Presumably this is due
to other signals that provide a different context to FRAP and
STAT signaling, but the mechanisms that mediate this
changing context remain to be identified. In our in vitro
stem cell system, this potentially translates into a density-
mediated signal. Our results add FRAP to a growing list of
signaling molecules whose actions are redirected from self-
renewal/proliferation to gliogenesis during development.
A novel mechanism for signal integration
Our results suggest that the immunophilin FKBP12 is in-
volved in glial differentiation, but its exact role is unclear.
FKBP12 binds TGF  receptors (Wang et al., 1996) and in-
hibits the basal activity of the receptor in the absence of
ligand (Chen et al., 1997). We show that FKBP12 com-
plexes with BMPR-IA in stem cells and is released upon
binding of BMP4 to its receptor (Fig. 5). The timing of the
release of FKBP12 from the BMP receptor correlates with
activation of Stat3 ( 6 h), suggesting that FKBP12 is also
involved in the kinetics of FRAP activation. FKBP12 can
complex with the antibiotic drugs FK506 and rapamycin to
inhibit distinct signaling pathways. FK506 binding to
FKBP12 inhibits the activity of calcineurin in T cells, caus-
ing immunosuppression (Clipstone et al., 1994), whereas ra-
pamycin binding to FKBP12 inhibits the activation of
FRAP (Hamilton and Steiner, 1998). We show that rapa-
mycin, but not FK506, specifically inhibits the BMP-medi-
ated augmentation of Stat3 activation and glial differentia-
tion (Fig. 6). It is important to note that all our studies are
performed with endogenous cellular proteins, with the ex-
ception of dominant-negative inhibitory proteins that we
have overexpressed. This, and the fact that our cultures are
dynamically undergoing differentiation, may allow us to
speculate on novel functions for FKBP12. We could not iso-
late a complex of FKBP12 and FRAP in BMP-treated cells
(unpublished data), in agreement with a previous crystallo-
graphic analysis showing that FKBP12 does not bind di-
rectly to FRAP (Choi et al., 1996). FKBP12 may complex
with other proteins, or be modified, as it is released from the
receptor. The intrinsic peptidyl-prolyl isomerase activity
(Siekierka et al., 1990) may be significant in these signaling
interactions. The region of FRAP required for binding to
FKBP12–rapamycin complex is also required for the activa-
tion of its serine-threonine kinase activity (Vilella-Bach et
al., 1999). This may suggest an endogenous cellular ana-
logue of rapamycin that functions in FKBP12-mediated ac-
tivation of FRAP. However, we cannot discount the likeli-
hood that FKBP12 is acting strictly as an inhibitor of both
BMP receptor and FRAP activity, so the signaling molecules
linking BMP receptor activation with FRAP activation re-
main undetermined.
The serine-threonine kinase FRAP is an important regu-
lator of cell growth and proliferation (Hentges et al., 2001;
Fingar et al., 2002). FRAP acts by promoting the synthesis
of proteins crucial to increasing cell size and to cell cycle
progression (Gingras et al., 2001; Fingar et al., 2002).
FRAP activity is nutrient dependent and increases with ris-
ing amino acid levels and insulin signaling (Gingras et al.,T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 BMP-mediated fate choice in CNS stem cells | Rajan et al. 919
2001). One possibility is that rapamycin may mimic an en-
dogenous inhibitor of otherwise constitutively active FRAP
(Gingras et al., 2001). Overexpressed FRAP causes Stat3
phosphorylation at serine residue 727 (Yokogami et al.,
2000). This suggests a model where BMPs, by causing serine
phosphorylation of STAT proteins, can integrate with
other signals that tyrosine phosphorylate STAT proteins;
this concerted action would raise STAT activation above a
threshold required for differentiation to the glial fate and
would override a SMAD protein–mediated smooth muscle
fate (Fig. 8).
A number of recent studies show that stem cells from
many tissues can adopt a broad range of unexpected fates
(Valtz et al., 1991; Bjornson et al., 1999; Gussoni et al.,
1999; Jackson et al., 1999; Galli et al., 2000; Lagasse et al.,
2000). However, these results beg the question of how ex-
trinsic signals can control cell fate in such unexpected ways.
This study, along with our previous results (Tsai and
McKay, 2000; Panchision et al., 2001), demonstrate that
defined pathways remain accessible to stem cells throughout
development. As there is increasing evidence that stem cells
continuously monitor morphogenic signals to make deci-
sions regarding identity and self-renewal (Hitoshi et al.,
2002b; Panchision and McKay, 2002), these fate-choice
mechanisms have increasing importance for understanding
development as well as designing therapeutic treatments.
Materials and methods
Materials
All tissue culture reagents were obtained as previously described (Johe et
al., 1996; Rajan and McKay, 1998).
Antibodies. The following antibodies were used: monoclonal anti-GFAP
from ICN Biomedicals; polyclonal anti-GFAP from DakoCytomation;
monoclonal anti-SMA and anti-FLAG from Sigma-Aldrich; polyclonal anti-
HA from BABCO; monoclonal anti-FKBP12, anti-FRAP, and anti-Stat3
from Transduction Laboratories; polyclonal anti-phosphoStat3 (Tyr705 and
Ser727) from Santa Cruz Biotechnology, Inc.; monoclonal anti–BMPR-IA
from R&D Systems; polyclonal anti-phosphoSmad1/5/8 (a gift of P. ten
Dijke, Netherlands Cancer Institute, Amsterdam, Netherlands; or pur-
chased from Cell Signaling); fluorescent-labeled secondary antibodies
from Jackson ImmunoResearch Laboratories; and peroxidase-conjugated
secondaries for ECL from Boehringer. 
Other reagents. Other reagents included ECL reagents from Pierce
Chemical Co., polyacrylamide gradient gels from Novex, protein A–Seph-
arose from Amersham Biosciences, Ponceau S from Sigma-Aldrich, Lipo-
fectamine Plus from Invitrogen, rapamycin and  -amanitin from Calbio-
chem, FK506 from American Qualex, and BMP2 and BMP4 from Genetics
Institute. 
Plasmids. The Stat3 mutant (a gift from J.E. Darnell, The Rockefeller Uni-
versity, New York, NY) has a three amino acid substitution in the DNA
binding domain as previously described (Horvath et al., 1995) and was
tagged with a synthetic FLAG epitope. The Smad7 construct (a gift from P.
ten Dijke, Netherlands Cancer Institute, Amsterdam, Netherlands) (Ishisaki
et al., 1999) was modified such that it expressed the protein with an NH2-
terminal HA epitope under the control of the  -actin promoter (a gift from
J. Rossant, Children’s Hospital, Toronto, Canada). The kinase-dead FRAP
construct has a Trp2027 to Phe inactivating mutation in the kinase domain
(Vilella-Bach et al., 1999). The FRB-defective FRAP construct has an
Asp2357 to Glu mutation that prevents protein interactions via the FRB do-
main (Vilella-Bach et al., 1999). Both FLAG constructs (gifts from J. Chen,
University of Illinois, Urbana-Champaign, IL) were tagged with an NH2-
terminal synthetic FLAG epitope.
Cell culture and treatments
Embryonic and adult rat stem cells were grown as previously described
(Johe et al., 1996; Rajan and McKay, 1998). To grow adult stem cells, ven-
tricular and subventricular tissue was dissected from the brains of young
adult female rats (200–250 g weight), enzymatically dissociated, and
plated in serum-free DME/F12 medium with N2 supplement. bFGF was in-
cluded at 10 ng/ml to promote rat stem cell proliferation. Stem cells from
E13 mouse cortex were required for one experiment using a mouse-spe-
cific Stat3 (pSer727) antibody and were grown as described for rat, except
mouse cells were incubated in 5% oxygen and 20 ng/ml bFGF. Cells were
fed with bFGF daily, and medium was replaced on alternate days during
stem cell expansion. Passaging was performed nonenzymatically using
Ca
2 /Mg
2 -free HBSS. All experiments were performed on first- or second-
passage cells.
For mass culture experiments, cells were plated at 7,000 cells/cm
2 and
BMP treatment was initiated after 1 d (low density) or 4 d (high density).
Alternatively, cells were plated at 350 cells/cm
2 and BMP treatment was
initiated immediately (low density) or after 4 d (high density). For clonal
analysis, cells were plated at 35 cells/cm
2 and BMP treatment was initiated
immediately (low density) or after 6 d (high density). BMP4 was added
daily, usually for 2 d in the presence of bFGF and for another 4 d after
bFGF withdrawal to promote efficient terminal differentiation of stem cells.
Drug inhibition experiments were performed using the 350 cells/cm
2
plating paradigm described above. When needed, CNTF (10 ng/ml), rapa-
Figure 8. Model for recruitment of BMP 
signals in fate choice decisions. BMP4 
causes the activation of at least two 
signaling pathways in neural stem cells. 
Upon ligand–receptor binding, the BMPR 
receptor complex releases FKBP12 and 
activates SMAD proteins, resulting 
in smooth muscle differentiation. 
The released FKBP12 may bind with 
rapamycin to inhibit FRAP or may act in 
some modified form to activate FRAP. 
FRAP then catalyzes serine phosphory-
lation (S*) of STAT to augment its prior 
activation by tyrosine phosphorylation 
(Y*) by another signal. High cell density 
(described in text) acts to promote basal 
STAT activation and DNA binding by an 
unknown signaling mechanism. This 
enhanced activation of STAT (Y*S*) causes 
efficient glial differentiation. Levels of 
activated STAT proteins in the cell dictate 
whether the STAT or SMAD signal 
acquires precedence in the fate choice 
between smooth muscle and glia.T
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mycin (1  M), or FK506 (1  g/ml) were used in the same manner as BMP4.
Separate experiments involving BMP/CNTF cotreatment were performed
using the 7,000 cells/cm
2 plating paradigm; cells were treated with BMP4
for 3 d in the presence of bFGF and for another 3 d in the absence of bFGF.
For the biochemical assays, cells were treated with factors and harvested
at the time points mentioned in the figure legends. For transcriptional inhibi-
tion experiments, cells were preincubated with  -amanitin (5  g/ml) for 20
min before and along with BMP treatment before harvesting of cells. Trans-
fections were performed with Lipofectamine Plus reagent according to the
manufacturer’s instructions (Invitrogen). For Stat3 and Smad7 manipula-
tions, cells were plated at 3,500 cells/cm
2 and cultured with 10 ng/ml bFGF
for 1 d before transfection and for 3 d after transfection to allow the domi-
nant-negative Stat3–FLAG or Smad7–HA plasmid to express before BMP4
treatment. Cells were then treated with 10 ng/ml BMP4 for 3 d with bFGF
mitogen and for 3 d after mitogen withdrawal. For FRAP manipulations,
cells were plated at 350 cells/cm
2 and cultured with 10 ng/ml bFGF for 4 d
before transfection and for 1 d after transfection to allow the kinase-dead or
FRB-defective FRAP plasmid to express before BMP4 treatment. The trans-
fection efficiency was  10%, as measured by epitope tag staining.
Immunofluorescent staining of cells
Cells were fixed with 4% paraformaldehyde for 10–15 min at room tem-
perature, blocked for 30 min in PBS with 0.1% triton and 5% normal goat
serum, and incubated with the primary antibody for 2–4 h at room temper-
ature. Cells were stained as directed with anti-SMA to detect smooth mus-
cle cells and anti-GFAP to detect glia. After two washes in PBS, the sec-
ondary antibody was applied at a 100-fold dilution for 1 h at room
temperature. Cultures were then washed with PBS and mounted in
Vectashield containing DAPI (Vector Laboratories). Images were photo-
graphed under fluorescent filters using a Carl Zeiss MicroImaging, Inc. Ax-
ioplan microscope and Spot digital camera (Diagnostic Instruments, Inc.).
Statistical analysis and histogram illustration of cell numbers were per-
formed using SigmaPlot 5.0 (SPSS, Inc.). Other graphic illustrations were
generated using Powerpoint for Windows (Microsoft). All images were
combined for figures using Adobe Photoshop 5.0
® for Windows.
EMSA
Nuclear extract preparation and EMSA were performed as described previ-
ously (Rajan and McKay, 1998). Autoradiography was performed using
Biomax Mr film (Eastman Kodak Co.), and images were digitally imported
using a Duoscan T2500 flatbed scanner (AGFA) and processed for figures
using Adobe Photoshop 5.0
® for Windows.
Immunoprecipitation and immunoblotting
Total cell lysates were prepared in nondenaturing lysis buffer (1% Triton
X-100, 10% glycerol, 50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EGTA, 2 mM
MgCl2, 1 mM DTT, 1 mM PMSF, and phosphatase inhibitors) and were nor-
malized for protein concentration. For immunoprecipitation, normalized ly-
sates were incubated with primary antibody overnight at 4 C. After incuba-
tion with protein A–Sepharose (1:1 vol/vol), the immune complexes were
washed twice with PBS and heated to 70 C in SDS-PAGE loading buffer.
Samples were resolved in denaturing gels and transferred onto nitrocellu-
lose. Filters were blocked overnight in Tris-buffered saline (20 mM Tris, pH
7.6, 137 mM NaCl) with 0.1% Tween 20 (TBST) containing 3% bovine se-
rum albumin. Filters were incubated with primary antibody (1:1,000 dilu-
tion in blocking buffer) for 4 h at room temperature and then washed three
times in TBST for 1 h. Filters were then incubated with the appropriate sec-
ondary antibody (1:20,000 dilution in blocking buffer) for 1 h and then
washed for 1 h. Relevant bands were detected with ECL according to the
manufacturer’s instructions. Ponceau S staining (0.1% in 5% acetic acid)
was performed for 30 s, followed by destaining in several changes of puri-
fied water. Banding patterns were digitally scanned as described above.
BMP2 and BMP4 were obtained by agreement with Genetics Institute. 
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